HC Wainwright Rates SAB Biotherapeutics (SABS) buy

HC Wainwright maintains its positive stance on SAB Biotherapeutics with a $10.00 price target, a 159.07% upside from the current price.

By EarningsIQ Research Desk · Published Jun 16, 2026, 2:05 AM EDT · Updated Jun 18, 2026, 1:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated SAB Biotherapeutics, Inc. ($SABS) "buy" with a $10 price target on June 15, 2026.

Since the rating, $SABS is up 0.8% after 1 week, down 7.2% after 1 month and down 35.1% to date (from the $3.90 close on Jun 15, 2026).

SABS SAB Biotherapeutics, Inc.

$2.53 -32.89% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright analyst Emily Bodnar reiterated a buy rating on SAB Biotherapeutics, Inc. (NasdaqCM: SABS) with a $10.00 price target on June 15, 2026.
HC Wainwright's $10 price target implies 159.07% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.86 share price.
The stock traded around $3.86 on Tuesday, sitting well within its 52-week range of $1.85 to $5.15 while holding a P/E ratio of 14.12.
Barclays also covers the clinical-stage biotech firm, having initiated an overweight rating with a $13.00 price target on June 24, 2026.

Get $SABS trade alerts by text

We text you when insiders, Congress or big funds trade $SABS. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SAB Biotherapeutics, Inc. alert may contain errors. Disclosures

HC Wainwright Reaffirms Outlook on SAB Biotherapeutics

HC Wainwright is sticking with its positive stance on SAB Biotherapeutics, Inc. (NasdaqCM: SABS). Analyst Emily Bodnar reiterated a buy rating on the clinical-stage biopharmaceutical company on June 15, 2026, keeping a $10.00 price target on the shares. The firm's ongoing support comes as the company continues advancing its clinical pipeline for antibody therapies.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics traded at $3.86 on Tuesday. The stock changes hands inside a 52-week range spanning from a low of $1.85 to a high of $5.15. The company carries a market capitalization of roughly $308.4 million and a P/E ratio of 14.12, alongside a forward P/E of -3.55.

12-month forecast

$SABS price target

SAB Biotherapeutics, Inc. daily closes and this analyst's $10 target. Not advice.

Analysts Set New Price Targets

Other Wall Street firms are also tracking the biotech company's progress. Barclays initiated coverage on the stock on June 24, 2026, assigning an overweight rating and a $13.00 price target. Across the broader analyst community tracked by market data, the stock holds a consensus mean price target of $11.64 backed by 11 analyst opinions.

Inside SAB Biotherapeutics

SAB Biotherapeutics focuses on developing human polyclonal immunotherapeutic antibodies to target immune system disorders and infectious diseases. Its lead candidate, SAB-142, is currently in Phase 2b clinical trials as a potential treatment for autoimmune type 1 diabetes. Headquartered in Miami Beach, Florida, the company employs 86 people.

What to Watch at SAB Biotherapeutics, Inc.

Investors will look toward the company's next earnings report, scheduled for November 12, 2026, for further financial updates on its clinical trials and operational progress.